Loco-Regional Hyperthermia

   
Loco-Regional Hyperthermia

The ONCOTHERM EHY-2000 Plus receives a Certificate of Grant for in-situ IMMUNOTHERAPY

TUMOUR VACCINATION PATENT

Learn more about this patent

Immune System Support - Cancer

A method for non-invasive treatment of primary cancer and its metastases or for prevention of relapse of a cancer disease comprising administering an immune stimulant to a patient in association with radiofrequency waves using capacitive coupling in a condenser arrangement

…ESPECIALLY

AN IN-SITU AND IN VIVO VACCINATION METHOD FOR TREATMENT OF PRIMARY CANCER AND ITS METASTASES EVEN IN DISSEMINATED CELL STATES

AND FOR ENABLING AND SUPPORTING THE PATIENT’S OWN IMMUNE SYSTEM TO RECOGNIZE AND KILL THE CANCER CELLS AND TO BUILD UP A MEMORY TO PREVENT RELAPSE OF A CANCER DISEASE.

Loco-Regional Hyperthermia (LRHT) with the Oncotherm EHY-2000 Plus, using the technique of...

modulated Electro-Hyperthermia (mEHT)

LRHT is based on the classical method of Hyperthermia (high-heat) but does more than just randomly heat layers of tissue. mEHT employs a modulated electric field to selectively deliver a controlled energy dose to a localized treatment area. A mobile electrode is positioned on the treatment area, while a second stationary electrode remains in a fixed position below the patient, integrated within the therapy bed. Operating at a carrier frequency of 13.56 MHz, this capacitive coupled impedance balancing circuit delivers controlled energy directly to the malignant cells.

Microbiological tests have demonstrated that higher ionic concentrations exist in the more active malignant cellular environment. Consequently, the extracellular matrix of malignant tissue inherently has greater conductivity and permittivity than healthy tissue. This difference facilitates selective focus on malignant cells even in highly mixed tissue containing large numbers of healthy and malignant cells. The derived advantage is the RF field tends to flow predominantly through the tumour tissue where concentration of the focused field and the associated energy absorption heats the malignant cells.

This process of natural selection is further enhanced by the electric-field modulation, which addresses the autonomous, non-collective behavior of individual malignant cells by reengaging the body’s inherent immune response. Ultimately, malignant cells are then driven to achieve “apoptosis”.

apoptosis-1

This effect of modulated electric field is unique and exclusive to therapy with the Oncotherm device.

Can LRHT be combined with other forms of treatment?

LRHT is intended for use as an adjunct to chemotherapy and radiotherapy, and is devoted to the non-invasive hyperthermia based treatment of indicated solid tumour cancers. LRHT has proven to be complementary to these treatments by enhancing the beneficial effects of chemotherapy and radiation while helping to mitigate side effects. Even a tumour which has developed a resistance to chemotherapy and radiation, may respond again to these therapies following LRHT treatment.

Are there any adverse side-effects to LRHT?

This complementary therapy presents minimal risk and limited adverse side effects. Heating the tumour has minimal effect on adjacent healthy tissue; however, some slight surface skin reddening can occur. This effect is mitigated through regular patient communication during treatment. Also, the body’s natural circulation is extremely efficient and soon dissipates the heat – something the tumour is not capable of because of its more primitive blood supply.

LRHT Treatment-1
LRHT Treatment Positioning
  • LRHT with mEHT can be used to treat indicated solid tumors and has proven synergies as an adjunct to current standards of care. LRHT is safe, non-invasive, uses no x-rays, and demonstrates no side effects. It can be successfully integrated with other protocols including chemotherapy, radiotherapy, immunotherapy, surgery and naturopathic treatments.
  • LRHT with mEHT sensitizes the tumor to complementarily applied chemotherapy because constrained thermodynamic flow effects destabilize the cell membrane, increasing its permeability and structural dysfunction, thereby increasing the absorption rate of the administered chemo agent. LRHT compromises the tumor cell membrane allowing higher intracellular drug concentrations. The positive results of phase II/III trails have established that LRHT with chemotherapy is a novel clinical modality that allows the chemotherapy to be better targeted within the heated tumour.
  • LRHT with mEHT sensitizes the tumor to complementarily applied radiotherapy by oxygenation (increased oxygen delivery to the cells via blood perfusion). The addition of LRHT during a series of radiotherapy treatments improves relevant clinical endpoints such as response rate, local control and overall survival. LRHT increases oxygenation, thus reducing hypoxia and amplifying the radiation cytotoxic effect. LRHT also inhibits the repair of radiation damaged tumor cells.
  • LRHT with mEHT triggers immunogenic cell-death caused via its in-situ vaccine component activation of the adaptive immune system to fight against the cancer cells. The immune stimulant, as a component of the tumour vaccine, supports this fight so that the effect is completely systemic having long-term memory.
  • LRHT with mEHT triggers antigen expression through the compromised malignant cellular membrane. Of particular significance is the release of heat shock proteins (HSP) that promotes a natural immune response destructive to the tumour. Danger signals such as mobility group B1 protein, ATP and HSP, which are released from treated necrotic tumor cells, stimulate the natural immune system and therefore assist the anti-tumour response.
  • LRHT with mEHT stimulates the re-establishment of adherent connections (β-catenins, E-cadherins) that play a key role in triggering apoptosis and suppressing malignant cell dissemination.
  • LRHT with mEHT activates the P53 tumour suppression gene.
  • LRHT with mEHT has application in the post-surgical setting to promote healing.
cccslider-4

IHC Online Resource Library

Visit our online Resource Centre to learn more about LRHT as well as other integrative protocols.

Integrative Medicine

Dr. Parmar's Hyperthermia Lecture

oncanp-logo
Dr. Gurdev Parmar, B.Sc., ND was a keynote speaker for the Oncology Association of Naturopathic Physicians (OncANP) inaugural Naturopathic Oncology Conference. Please click on the OncANP logo to view Dr. Parmar’s presentation on Hyperthermia in Oncology.

Why IHC-CCC for LRHT?

  • IHC is the first clinic in North America to introduce LRHT
  • IHC is the most experienced LRHT clinic in North America
  • IHC is the only clinic to have done research on LRHT
  • IHC utilizes the only Health Canada Class 3 licensed device
  • IHC has 15 years experience in patient focused cancer care
  • IHC was recently selected for participation in an Advanced Integrative Oncology Study (CUSIOUS)

Doctors providing this service

Dr. Gurdev Parmar ND

Dr. Lindsay Adrian ND

Dr. Rigo Kefferputz ND

Dr. Eric Boudreau ND

Dr. Erin Rurak ND

APPOINTMENT

To request an appointment for a consultation or service, simply click here, fill out the request form, and one of our Patient Care Coordinators will contact you.

HAVE A QUESTION?

If you have a question about our consultations, services, or procedures, simply click here, fill out the contact form, and one of our Patient Care Coordinators will contact you.

INTAKE FORMS

To download our New Patient intake forms, simply click here, then select the applicable form.